Navigation Links
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
Date:2/26/2009

will be evaluated in comparison to placebo. Ambulatory patients suffering from mild to moderate Alzheimer's disease are randomized and receive oral treatment, twice a day, of either 40 or 80 mg of EHT 0202, or placebo over a three-month period. The study design will also allow for the collection of preliminary data related to many clinical efficacy parameters of EHT 0202, notably including a battery of cognitive assessments (ADAS-Cog, NTB, MMSE) but also assessment of patients' daily living activities, global assessment and behaviour.

Study results will be available in Q4 2009.

About EHT 0202

EHT 0202 has a novel mechanism of action when compared to existing Alzheimer's disease therapeutics: it stimulates the alpha-secretase pathway, thus enhancing the production of the procognitive and neuroprotective sAPPalpha fragment of APP (Amyloid Precursor Protein). The stimulation of the alpha-secretase pathway being to the detriment of Abeta amyloid peptide production, EHT 0202 potentially reduces toxic Abeta plaque formation [1].

Phase I studies demonstrated good tolerability of EHT 0202 in both young and aged healthy volunteers; importantly, no sedation or emesis were observed clinically.

Preclinical studies have shown that EHT 0202 protects cortical neurons against Abeta42-induced stress and that this neuroprotection is associated with sAPPalpha induction. EHT 0202 has also demonstrated pro-cognitive properties in several animal models: age-related memory impairment and scopolamine-induced amnesia [2].

About Alzheimer's disease

Alzheimer's disease is the most frequent cause of dementia in the aging population. The World Health Organization estimated in 2001 that 18 million people around the world were suffering from Alzheimer's disease and that this figure could nearly double by 2025 to 34 million [3].

About ExonHit Therapeutics


'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... U.S. Food and Drug Administration (FDA) approved ... of INTELENCE ® (etravirine), a non-nucleoside reverse transcriptase ... virus (HIV-1) in treatment-experienced adults with resistance to an ... The recommended oral dose of INTELENCE tablets is 200 ...
... KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... with its subsidiary collectively as the "Group" - 801.HK), ... announce that the Company has obtained the approvals from ... Futures Bureau for its proposed offering and listing of ...
Cached Medicine Technology:FDA Approves New Dosage Strength for INTELENCE® 2FDA Approves New Dosage Strength for INTELENCE® 3FDA Approves New Dosage Strength for INTELENCE® 4FDA Approves New Dosage Strength for INTELENCE® 5Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering 2
(Date:9/19/2014)... September 19, 2014 The Alliance ... partnership with the National Fire Protection Association (NFPA), ... collaboration, formalized today in a Memorandum of Understanding ... factories, workers and other stakeholders with information, guidance ... protect the health and safety of workers in ...
(Date:9/19/2014)... 2014 "I have difficulty putting in ... to stretching the skin around my eyes during the ... me to design a more convenient method of performing ... provides a quicker, easier, more sanitary method of putting ... this task manually, saves time and effort, and helps ...
(Date:9/19/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2
... Dietary Guidelines (i.e., men who usually drink more than two ... one drink per day) or those who binge drink are ... new study accepted for publication in The Endocrine Society,s ... metabolic syndrome consists of a series of risk factors and ...
... Shows Overuse of Technology Is Wreaking ... Havoc on Romance -, ... juggling lengthy to-do lists, jam-packed schedules, and the 24/7,demands of children and ... wired lifestyle allows people to stay,connected with more friends, family and co-workers ...
... following news tips are based on poster and oral presentations ... in Chicago from July 26 to July 31. Each presentation ... Brain Atrophy and Biomarkers May Help Identify People at Risk ... Department of Psychiatry, NYU Langone Medical Center , EMBARGOED FOR ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ) updates and corrects ... 2008 net income is expected to,range from approximately $13.1 million ... which is changed from the previously announced net,income of $11.5 ... per,share., ABOUT VNUS MEDICAL TECHNOLOGIES, INC., VNUS is ...
... and Charitable Care and Coverage, OAKLAND, Calif., ... has approved more than 415 community benefit grants ... quarter of 2008.,The quarter,s contributions continue to support ... measurable impact on the health of,its communities., ...
... PORTLAND, Ore., July 29 Sometimes the simplest ... to health care --,are the most difficult., Regence ... company has launched a Web site that enables consumers ... health-related topics., The video cards are part of ...
Cached Medicine News:Health News:Drinking in excess associated with increased risk for metabolic syndrome 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 3Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 4Health News:New Alzheimer's predictors advance earlier detection 2Health News:New Alzheimer's predictors advance earlier detection 3Health News:New Alzheimer's predictors advance earlier detection 4Health News:New Alzheimer's predictors advance earlier detection 5Health News:New Alzheimer's predictors advance earlier detection 6Health News:New Alzheimer's predictors advance earlier detection 7Health News:New Alzheimer's predictors advance earlier detection 8Health News:VNUS Revises Upward Full-Year 2008 Net Income Guidance 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 3Health News:Regence Video Cards Help Start Important Health Conversations With Friends, Family 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: